NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
Recruiting · NCT07680699 · Registry updated 2026-07-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, cutaneous melanoma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-07-02 | NCT07680699 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AC Camargo Cancer Center | 12 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| AC Camargo Cancer Center | São Paulo | Brazil | 1 |